Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript

European Journal of Haematology

Volumn 92, Issue 3, 2014, Pages 263-267

  Masuzawa, Aki ^a   Kiyotani, Chikako ^a   Osumi, Tomoo ^a   Shioda, Yoko ^a   Iijima, Kazutoshi ^b,c   Tomita, Osamu ^b   Nakabayashi, Kazuhiko ^b   Oboki, Keisuke ^b   Yasuda, Kazuki ^d   Sakamoto, Hiromi ^e   Ichikawa, Hitoshi ^e   Hata, Kenichiro ^b   Yoshida, Teruhiko ^e   Matsumoto, Kenji ^b   Kiyokawa, Nobutaka ^b   Mori, Tetsuya ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Dasatinib; Imatinib; Precursor B cell acute lymphoblastic leukemia; SNX2 ABL1; Tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA; SNX2-ABL1; TYROSINE KINASE INHIBITORS;

CHILD; CHROMOSOMES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; SEQUENCE ANALYSIS, DNA; SORTING NEXINS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84894234847     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12234     Document Type: Article

References (19)

1. De Braekeleer E, Douet-Guilbert N, Rowe D, et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011;86:361-71.
2. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
3. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-9.
4. Eyre T, Schwab CJ, Kinstrie R, et al. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012;120:4441-3.
5. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22:153-66.
6. Mustjoki S, Hernesniemi S, Rauhala A, et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009;94:1469-71.
7. Soler G, Radford-Weiss I, Ben-Abdelali R, et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia 2008;22:1278-80.
8. Zuna J, Zaliova M, Muzikova K, et al. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosom Cancer 2010;49:873-84.
9. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1- positive T-cell acute lymphoblastic leukemia. Leukemia 2009;23:627-9.
10. Ernst T, Score J, Deininger M, et al. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol 2011;53:43-6.
11. McPherson A, Hormozdiari F, Zayed A, et al. R deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011;7:e1001138.
12. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
13. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
14. Carlton J, Bujny M, Rutherford A, Cullen P. Sorting nexins-unifying trends and new perspectives. Traffic 2005;6:75-82.
15. Haft CR, de la Luz Sierra M, Barr VA, Haft DH, Taylor SI. Identification of a family of sorting nexin molecules and characterization of their association with receptors. Mol Cell Biol 1998;18:7278-87.
16. Van Limbergen H, Beverloo HB, van Drunen E, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosom Cancer 2001;30:274-82.
17. De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005;105:4849-52.
18. Hidalgo-Curtis C, Chase A, Drachenberg M, et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosom Cancer 2008;47:379-85.
19. Meijerink JP, den Boer ML, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 2009;46:16-23.